SCHEMBL634186

SCHEMBL634186

COc1ccc(/C=C/C(=O)c2ccc(OC)cc2O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 7/20 1.00
MAPT P10636 6/20 1.00
APP P05067 5/20 1.00
LMNA P02545 3/20 1.00
MEN1 O00255 3/20 1.00
MAPK1 P28482 3/20 1.00
KMT2A Q03164 3/20 1.00
CYP3A4 P08684 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
CYP2C19 P33261 2/20 1.00
ALDH1A1 P00352 2/20 0.89
HPGD P15428 2/20 0.89
ALOX15 P16050 2/20 0.89
HSD17B10 Q99714 2/20 0.89
TP53 P04637 1/20 0.89
MAOB P27338 4/20 0.84
CTSL P07711 1/20 0.84
NPC1 O15118 1/20 0.84
RECQL P46063 1/20 0.84
RAB9A P51151 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25189208 1.00 ABCG2 (1.00) ABCG2MAPTAPPLMNAMEN1
SCHEMBL30384538 1.00 ABCG2 (1.00) ABCG2MAPTAPPLMNAMEN1
SCHEMBL30382670 1.00 ABCG2 (1.00) ABCG2MAPTAPPLMNAMEN1
SCHEMBL634187 1.00 ABCG2 (1.00) ABCG2MAPTAPPLMNAMEN1
SCHEMBL25188859 0.98 ABCG2 (0.97) ABCG2MAPTAPPLMNAMEN1
SCHEMBL30383218 0.95 ABCG2 (0.91) ABCG2MAPTAPPLMNAMEN1
SCHEMBL5515065 0.95 ABCG2 (0.91) ABCG2MAPTAPPLMNAMEN1
SCHEMBL5515061 0.95 ABCG2 (0.91) ABCG2MAPTAPPLMNAMEN1
SCHEMBL25219780 0.94 MAPT (1.00) ABCG2MAPTAPPLMNAMEN1
SCHEMBL633177 0.94 MAPT (1.00) ABCG2MAPTAPPLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3562803-B1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) 2025-10-15 EP claimed
US-20210363121-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) 2021-11-25 US claimed
US-20190337916-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2019-11-07 US claimed
CN-117510486-A Flavonol derivative containing thiadiazole, and preparation method and application thereof 贵州大学 2024-02-06 CN disclosed
US-20210363121-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) 2021-11-25 US disclosed
CN-110862883-A Anti-mite and anti-oxidation medicated soap for expelling and killing mites and preparation method thereof 上海制皂有限公司 2020-03-06 CN disclosed
US-20190337916-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2019-11-07 US disclosed
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-01-10 US disclosed
WO-2017132135-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-03 WO disclosed
US-20160220510-A1 ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-08-04 US disclosed
US-8946287-B2 Chemotherapeutic flavonoids, and syntheses thereof PURDUE RESEARCH FOUNDATION (US) 2015-02-03 US disclosed
US-20100099755-A1 CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF PURDUE RESEARCH FOUNDATION (US) 2010-04-22 US disclosed
US-20090074820-A1 AMINOARYLVINYL-S-TRIAZINE COMPOUNDS AND USES THEREOF L'OREAL (FR) 2009-03-19 US disclosed
US-20090074820-A1 AMINOARYLVINYL-S-TRIAZINE COMPOUNDS AND USES THEREOF L'OREAL (FR) 2009-03-19 US disclosed
US-20080319051-A1 LIQUIRITIGENIN AND DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS BIONOVO, INC. (US) 2008-12-25 US disclosed
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed
US-20060270614-A1 Use of chalcones for the treatment of viral disorders JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2006-11-30 US disclosed
US-4605674-A VIRICIDES HOFFMANN-LA ROCHE INC. (US) 1986-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 ABCG2 5/4885MAPT 4566/4885APP 3206/4885
US-20100099755-A1 CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF NRAS, FAU, DPYD ABCG2 7/4885MAPT 1962/4885APP 3793/4885
US-20190337916-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA NOTCH1, DNER, NOTCH2 ABCG2 2354/4885MAPT 4067/4885APP 462/4885
US-20080319051-A1 LIQUIRITIGENIN AND DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS GPER1, ESR1, ESR2 ABCG2 876/4885MAPT 1735/4885APP 2457/4885
US-20060270614-A1 Use of chalcones for the treatment of viral disorders HAVCR2, HMGB3, EIF2AK2 ABCG2 3800/4885MAPT 788/4885APP 2865/4885
US-20160220510-A1 ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS AARS1, EPRS1, EEF1G ABCG2 1123/4885MAPT 1595/4885APP 4107/4885
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF ESRRG, GPER1, ESR2 ABCG2 3643/4885MAPT 4210/4885APP 4219/4885
US-20090074820-A1 AMINOARYLVINYL-S-TRIAZINE COMPOUNDS AND USES THEREOF TYR, AAAS, ALAD ABCG2 1628/4885MAPT 874/4885APP 1069/4885
US-20210363121-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA NOTCH1, DNER, NOTCH2 ABCG2 2354/4885MAPT 4067/4885APP 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.